Oncolytic Immunotherapy: Where Are We Clinically?
Following a century of preclinical and clinical work, oncolytic viruses are now proving themselves in randomized phase 3 trials. Interestingly, human data indicates that these agents have potent immunostimulatory activity, raising the possibility that the key consequence of oncolysis might be induct...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | Scientifica |
| Online Access: | http://dx.doi.org/10.1155/2014/862925 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832562160163618816 |
|---|---|
| author | Akseli Hemminki |
| author_facet | Akseli Hemminki |
| author_sort | Akseli Hemminki |
| collection | DOAJ |
| description | Following a century of preclinical and clinical work, oncolytic viruses are now proving themselves in randomized phase 3 trials. Interestingly, human data indicates that these agents have potent immunostimulatory activity, raising the possibility that the key consequence of oncolysis might be induction of antitumor immunity, especially in the context of viruses harboring immunostimulatory transgenes. While safety and efficacy of many types of oncolytic viruses, including adenovirus, herpes, reo, and vaccinia seem promising, few mechanisms of action studies have been performed with human substrates. Thus, the relative contribution of “pure” oncolysis, the immune response resulting from oncolysis, and the added benefit of adding a transgene remain poorly understood. Here, the available clinical data on oncolytic viruses is reviewed, with emphasis on immunological aspects. |
| format | Article |
| id | doaj-art-b5cfd2cd3a874090b50306c88b29d9a6 |
| institution | Kabale University |
| issn | 2090-908X |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Scientifica |
| spelling | doaj-art-b5cfd2cd3a874090b50306c88b29d9a62025-02-03T01:23:19ZengWileyScientifica2090-908X2014-01-01201410.1155/2014/862925862925Oncolytic Immunotherapy: Where Are We Clinically?Akseli Hemminki0Cancer Gene Therapy Group, Haartman Institute, University of Helsinki, Haartmaninkatu 3, 00290 Helsinki, FinlandFollowing a century of preclinical and clinical work, oncolytic viruses are now proving themselves in randomized phase 3 trials. Interestingly, human data indicates that these agents have potent immunostimulatory activity, raising the possibility that the key consequence of oncolysis might be induction of antitumor immunity, especially in the context of viruses harboring immunostimulatory transgenes. While safety and efficacy of many types of oncolytic viruses, including adenovirus, herpes, reo, and vaccinia seem promising, few mechanisms of action studies have been performed with human substrates. Thus, the relative contribution of “pure” oncolysis, the immune response resulting from oncolysis, and the added benefit of adding a transgene remain poorly understood. Here, the available clinical data on oncolytic viruses is reviewed, with emphasis on immunological aspects.http://dx.doi.org/10.1155/2014/862925 |
| spellingShingle | Akseli Hemminki Oncolytic Immunotherapy: Where Are We Clinically? Scientifica |
| title | Oncolytic Immunotherapy: Where Are We Clinically? |
| title_full | Oncolytic Immunotherapy: Where Are We Clinically? |
| title_fullStr | Oncolytic Immunotherapy: Where Are We Clinically? |
| title_full_unstemmed | Oncolytic Immunotherapy: Where Are We Clinically? |
| title_short | Oncolytic Immunotherapy: Where Are We Clinically? |
| title_sort | oncolytic immunotherapy where are we clinically |
| url | http://dx.doi.org/10.1155/2014/862925 |
| work_keys_str_mv | AT akselihemminki oncolyticimmunotherapywhereareweclinically |